Potential Clinical Role of Prokineticin 2 (PK2) in Neurodegenerative Diseases.
Alzheimer’s disease
Parkinson’s disease
Prokyneticin 2
clinical biomarkers
neuroinflammation
therapeutic targets
Journal
Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
11
2021
revised:
06
01
2022
accepted:
06
02
2022
pubmed:
13
4
2022
medline:
2
11
2022
entrez:
12
4
2022
Statut:
ppublish
Résumé
The role of the immune system in neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) has become clear in recent decades, as evidenced by the presence of activated microglia and astrocytes and numerous soluble mediators in the brain and peripheral tissues of affected patients. Among inflammatory mediators, chemokines play a central role in neuroinflammation due to their dual function as chemoattractants for immune cells and molecular messengers in crosstalk among CNS-resident cells. The chemokine Bv8/Prokineticin 2 (PK2) has recently emerged as an important player in many age-related and chronic diseases that are either neurodegenerative or systemic. In this perspective paper, we briefly discuss the role that PK2 and its cognate receptors play in AD and PD animal models and in patients. Given the apparent changes in PK2 blood levels in both AD and PD patients, the potential clinical value of PK2 either as a disease biomarker or as a therapeutic target for these disorders is discussed.
Identifiants
pubmed: 35410604
pii: CN-EPUB-122441
doi: 10.2174/1570159X20666220411084612
pmc: PMC9886845
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2019-2023Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
Brain. 2020 Oct 1;143(10):3077-3088
pubmed: 32830221
Neurogastroenterol Motil. 2012 Jan;24(1):65-75, e12
pubmed: 22050240
Parkinsonism Relat Disord. 2021 Sep;90:62-64
pubmed: 34392132
J Alzheimers Dis. 2014;38(2):281-93
pubmed: 23948942
Neuropharmacology. 2019 Nov 1;158:107739
pubmed: 31408628
Physiol Rev. 2018 Apr 1;98(2):1055-1082
pubmed: 29537336
Pharmacol Res. 2020 Feb;152:104593
pubmed: 31843673
Front Neurosci. 2021 Sep 01;15:733857
pubmed: 34539340
Neurosci Bull. 2017 Oct;33(5):515-525
pubmed: 28831680
Front Pharmacol. 2019 May 29;10:622
pubmed: 31231219
Mov Disord. 2020 Jan;35(1):180-184
pubmed: 31682033
Front Physiol. 2020 May 19;11:425
pubmed: 32508669
Pharmacol Res. 2020 Oct;160:105190
pubmed: 32937177
Biomedicines. 2019 Dec 09;7(4):
pubmed: 31835422
Nat Commun. 2016 Oct 05;7:12932
pubmed: 27703142
Curr Neuropharmacol. 2021;19(4):498-512
pubmed: 32564756
Parkinsonism Relat Disord. 2020 May;74:57-63
pubmed: 32335490
Parkinsonism Relat Disord. 2019 Apr;61:203-206
pubmed: 30348495
J Neuroimmunol. 1999 Jan 1;93(1-2):182-93
pubmed: 10378882
Mov Disord. 2022 Jan;37(1):228-230
pubmed: 34623702
Lancet. 2021 Apr 24;397(10284):1577-1590
pubmed: 33667416
Front Neurol. 2021 Jun 22;12:636139
pubmed: 34239490
Mov Disord. 2021 Apr;36(4):1031-1033
pubmed: 33404134
Science. 2005 Jun 24;308(5730):1923-7
pubmed: 15976302
Neuropharmacology. 2017 Apr;116:82-97
pubmed: 27989680
Sci Rep. 2015 Oct 19;5:15301
pubmed: 26477583
Front Pharmacol. 2021 Mar 01;12:640441
pubmed: 33732160
Science. 2016 Aug 19;353(6301):777-83
pubmed: 27540165
Front Neurol. 2021 Jun 07;12:654739
pubmed: 34163421
Nat Commun. 2019 Sep 2;10(1):3945
pubmed: 31477726
J Neural Transm (Vienna). 2021 Aug;128(8):1185-1193
pubmed: 34263354
Cells. 2019 Nov 13;8(11):
pubmed: 31766244